Follow The Filings

GLUE Monte Rosa Therapeutics Inc.

Health Care, filed as MONTE ROSA THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2

  • 2 Owners
  • Max 1.6%
  • $25M
  • 2 new

In 2026 Q2 James Silverman and Stanley Druckenmiller opened positions in Monte Rosa Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 1.6% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman New 1.6%
  2. Stanley Druckenmiller New 0.14%

Who owns GLUE

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 1.6% New 1.6% 745,000 $18M History
Stanley Druckenmiller, Duquesne Family Office 0.14% New 0.14% 297,600 $7.2M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by GLUE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All GLUE insider trades
  • None no insider bought on the open market
  • $1.5M sold by 5 insiders outside a trading plan
  • $2.2M sold by 4 insiders under 10b5-1 plans
  1. Markus Warmuth CEO
    Sale
    $220K 9,500 shares at $23.18 1.6% of stake
    Traded Jul 16 Filed Jul 17
    ↗
  2. Jennifer Champoux COO
    Planned sale
    $102K 4,351 shares at $23.38 6.5% of stake
    Traded Jul 15 Filed Jul 16
    ↗
  3. Sharon Townson Chief Scientific Officer
    Planned sale
    $140K 6,000 shares at $23.31 8.1% of stake
    Traded Jul 6 Filed Jul 7
    ↗
  4. Filip Janku Chief Medical Officer
    Planned sale
    $132K 5,407 shares at $24.50 8.2% of stake
    Traded Jun 30 Filed Jul 1
    ↗
  5. Filip Janku Chief Medical Officer
    Planned sale
    $138K 6,000 shares at $22.95 9.1% of stake
    Traded Jun 29 Filed Jun 30
    ↗
  6. Anthony M. Manning Director
    Sale
    $231K 10,000 shares at $23.11 100% of stake
    Traded Jun 29 Filed Jun 30
    ↗
  7. Filip Janku Chief Medical Officer
    Planned sale
    $882K 41,845 shares at $21.08 41% of stake
    Traded Jun 23–24 Filed Jun 25
    ↗
  8. Sharon Townson Chief Scientific Officer
    Planned sale
    $60K 3,000 shares at $20.00 4.2% of stake
    Traded Jun 23 Filed Jun 25
    ↗
  9. Jennifer Champoux COO
    Planned sale
    $44K 2,175 shares at $20.00 3.4% of stake
    Traded Jun 23 Filed Jun 25
    ↗
  10. Jennifer Champoux COO
    Planned sale
    $41K 2,176 shares at $19.00 3.4% of stake
    Traded Jun 17 Filed Jun 18
    ↗
  11. Sharon Townson Chief Scientific Officer
    Planned sale
    $57K 3,000 shares at $19.00 4.2% of stake
    Traded Jun 17 Filed Jun 18
    ↗
  12. Markus Warmuth CEO
    Planned sale
    $106K 5,466 shares at $19.44 0.9% of stake
    Traded Jun 1 Filed Jun 2
    ↗
  13. Sharon Townson Chief Scientific Officer
    Planned sale
    $119K 6,000 shares at $19.87 8.1% of stake
    Traded May 29 Filed Jun 1
    ↗
  14. Jennifer Champoux COO
    Planned sale
    $44K 2,175 shares at $20.00 3.4% of stake
    Traded May 27 Filed May 28
    ↗
  15. Jennifer Champoux COO
    Planned sale
    $41K 2,176 shares at $19.00 3.4% of stake
    Traded May 22 Filed May 26
    ↗

Also filed in the last 12 months, not counted as buying or selling: 17 option exercises, 8 sales to cover taxes, 6 stock grants, and 3 other transactions.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $75.62M $123.67M
Net income -$135.35M -$72.7M -$38.63M
Net margin * — -96.1% -31.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $236.21M $377.44M $393.18M
Total non-current assets * $67.54M $61.29M $55.47M
Total assets $303.76M $438.73M $448.66M
Total current liabilities $46.59M $156.95M $64.21M
Total non-current liabilities * $77.91M $58.85M $151.39M
Total equity $179.25M $222.94M $233.06M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$43.8M $42M -$22.8M
Cash from investing $88.8M -$44.45M -$101.83M
Cash from financing $27.49M $98.89M $30.35M
Net change in cash $72.49M $96.44M -$94.28M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.